Thermo Fisher Scientific Inc. (TMO) Stake Decreased by First American Trust FSB
First American Trust FSB lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.8% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 11,894 shares of the medical research company’s stock after selling 338 shares during the quarter. First American Trust FSB’s holdings in Thermo Fisher Scientific were worth $2,661,000 as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in TMO. Paloma Partners Management Co grew its position in shares of Thermo Fisher Scientific by 1,294.5% during the second quarter. Paloma Partners Management Co now owns 2,036 shares of the medical research company’s stock worth $421,000 after buying an additional 1,890 shares in the last quarter. Tower Research Capital LLC TRC acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth approximately $1,854,000. Colony Group LLC grew its position in shares of Thermo Fisher Scientific by 26.6% during the second quarter. Colony Group LLC now owns 4,442 shares of the medical research company’s stock worth $920,000 after buying an additional 933 shares in the last quarter. Select Equity Group L.P. grew its position in shares of Thermo Fisher Scientific by 2.2% during the second quarter. Select Equity Group L.P. now owns 1,144,832 shares of the medical research company’s stock worth $237,140,000 after buying an additional 24,907 shares in the last quarter. Finally, Orbimed Advisors LLC grew its position in shares of Thermo Fisher Scientific by 49.8% during the second quarter. Orbimed Advisors LLC now owns 583,500 shares of the medical research company’s stock worth $120,866,000 after buying an additional 194,100 shares in the last quarter. 86.92% of the stock is owned by institutional investors and hedge funds.
Thermo Fisher Scientific stock traded up $1.14 during mid-day trading on Friday, reaching $240.00. The company’s stock had a trading volume of 1,365,765 shares, compared to its average volume of 2,140,164. The company has a market cap of $95.17 billion, a PE ratio of 25.29, a P/E/G ratio of 1.54 and a beta of 1.08. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.84 and a quick ratio of 1.27. Thermo Fisher Scientific Inc. has a twelve month low of $194.51 and a twelve month high of $253.91.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, January 15th. Shareholders of record on Monday, December 17th will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date of this dividend is Friday, December 14th. Thermo Fisher Scientific’s payout ratio is 7.17%.
A number of research firms have recently weighed in on TMO. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $256.00 price target for the company in a research report on Wednesday, December 19th. Needham & Company LLC began coverage on shares of Thermo Fisher Scientific in a report on Wednesday, January 2nd. They issued a “strong-buy” rating and a $271.00 price objective for the company. Finally, Robert W. Baird lifted their price objective on shares of Thermo Fisher Scientific from $256.00 to $264.00 and gave the stock an “outperform” rating in a report on Thursday, October 25th. Three analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Thermo Fisher Scientific presently has an average rating of “Buy” and an average target price of $271.10.
In other Thermo Fisher Scientific news, Director Tyler Jacks sold 1,100 shares of the firm’s stock in a transaction on Tuesday, December 4th. The stock was sold at an average price of $251.98, for a total value of $277,178.00. Following the sale, the director now directly owns 5,879 shares in the company, valued at $1,481,390.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Stephen Williamson sold 9,500 shares of the firm’s stock in a transaction on Friday, December 7th. The shares were sold at an average price of $241.45, for a total value of $2,293,775.00. Following the completion of the sale, the chief financial officer now owns 44,124 shares in the company, valued at $10,653,739.80. The disclosure for this sale can be found here. Insiders sold 32,607 shares of company stock worth $7,972,085 over the last quarter. 0.49% of the stock is currently owned by company insiders.
WARNING: “Thermo Fisher Scientific Inc. (TMO) Stake Decreased by First American Trust FSB” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2019/01/11/thermo-fisher-scientific-inc-tmo-stake-decreased-by-first-american-trust-fsb.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Read More: Compound Annual Growth Rate (CAGR)
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.